कंपनी का अवलोकन
OnKure Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. The company functions within the Healthcare sector and specifically the Biotechnology industry, a domain characterized by high research expenditures and reliance on successful clinical trial outcomes before commercial viability is achieved. As of the latest data, the organization employs 45 individuals and holds a total market capitalization of $54.56M. The absence of reported annual revenue figures, combined with a market cap of $54.56M, indicates that the company is in an early-stage development phase where value is derived primarily from intellectual property and pipeline potential rather than current sales performance.
वित्तीय स्वास्थ्य
The company reports a net income of $-59,517,000 and an EBITDA of $-62,503,000, while revenue remains unreported in the available data. The significant gap between the reported net income and EBITDA figures reveals a substantial cost structure driven by non-operating expenses, likely including interest or other financial charges that impact the bottom line more heavily than core business operations. Free cash flow stands at $-31,100,750, indicating that the company is currently burning cash to fund its research and development activities, which limits immediate financial flexibility but is typical for clinical-stage entities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the pre-revenue nature of the business where no sales have been generated to calculate profitability percentages. On the liability side, the company holds $59.05M in cash against a debt obligation of $549,000, resulting in a debt-to-equity ratio of 0.98. Despite the reported debt, the cash reserves significantly outweigh liabilities, suggesting a balance sheet that is effectively un-leveraged and conservative regarding solvency risks. The current ratio is reported at 10.28, a figure that indicates exceptional short-term liquidity and the ability to cover short-term obligations with current assets more than ten times over. Return on Equity is -74.4% and Return on Assets is -44.5%, metrics that reveal management is currently deploying capital to generate negative returns, a standard characteristic of companies investing heavily in R&D before product launch.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is calculated at -1.40. The divergence between these metrics, particularly the negative forward P/E, implies that the market is pricing in future earnings expectations that are not yet realized, rendering traditional earnings-based valuation multiples inapplicable at this stage. The price-to-book ratio stands at 0.97, indicating that the market values the company at slightly less than its book value, which suggests the stock is trading close to its net asset worth rather than at a significant premium. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A because there is no revenue data, and the EV/EBITDA stands at 0.06, a negligible figure that highlights the company's lack of normalized earnings relative to its enterprise value. Regarding price action, the 52-week high is $5.10 and the 52-week low is $1.70. Without a specific current share price provided in the facts to calculate a precise percentage deviation, the stock's position within this range must be inferred solely from the existence of the $5.10 high and $1.70 low benchmarks which define the recent trading volatility. The beta value is listed as N/A, meaning that the company's historical price volatility relative to the broader market cannot be quantified using standard regression analysis based on the available data points.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated revenue streams to calculate growth rates. Consequently, there is no data to determine whether earnings are growing faster or slower than revenue, as the foundational sales figures required for such comparison are absent from the financial records. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%. This absence of dividend distribution means that the company retains all available capital, reinvesting it entirely into research, development, and operational scaling rather than returning cash to shareholders. The overall growth and income profile of OnKure Therapeutics is defined by a complete reliance on external capital markets to fund operations in the absence of organic revenue growth or dividend income.